compare cilostazol with ticlopidine for long-term efficacy and safety as an adjunctive antiplatelet therapy after coronary stenting.
Introduction
Coronary stenting is reported to reduce res tenosis after balloon coronary angioplasty 1-3). Cur rently, coronary stenting has become an established treatment for coronary artery disease and is widely utilized in interventional cardiology. Moreover, use of adjunctive antiplatelet agents has been found to decrease stent-associated thrombosis, and play a role in improving final outcomes 3). However, the prevention of stent-associated complications remains an important concern during the perfor mance of coronary stenting, even though the over all success rate for the procedure has improved. Complications comprise: 1) acute vessel occlu sion/closure due to thrombus formation occurring from immediately following to within 24 hours of the procedure;
2) subacute thrombosis occurring between 1 and 30 days after stenting; and 3) late coronary restenosis caused by intimal hyperplasia or proliferation of smooth muscle cells secondary to growth factors released from platelets, occurring between 3 weeks and 6 months after stent place ment. Aspirin, one of the most popular oral anti platelet agents, has been shown to reduce the fre quency of ischemic complications, including coro nary occlusion/thrombosis after coronary angio plasty3), but has no affect on restenosis4). Moreover, no optimum dose or duration of aspirin therapy following coronary stenting has been established. Ticlopidine, an oral thienopyridine, is a potent inhibitor of platelet aggregation, exhibits a maxi mum platelet inhibition 3 to 5 days after initiation, and is associated with a platelet aggregation recov ery that is slow once the drug is discontinued 5, 6) .
From the Stent Anticoagulation
Restenosis Study (STARS) data, the combination of aspirin and ticlopidine following coronary stenting was shown to have lower rates of subacute thrombosis than that seen with aspirin use alone 7). However, ti clopidine has a number of severe adverse clinical events, including agranulocytosis, hepatic impair ment, and thrombotic thrombocytopenic purpura (TTP).
Cilostazol is another potent oral antiplatelet agent with a more rapid onset of action that selec tively inhibits phosphodiesterase III, and is associat ed with a lower incidence of adverse effects [8] [9] [10] [11] [12] [13] [14] . In a prospective study of coronary stenting with con comitant aspirin and cilostazol, no thrombosis was observed even though cases of emergency stent placement were included 12). Two interesting small randomized studies comparing cilostazol and aspi rin suggested that cilostazol might reduce the inci dence of late restenosis with the exception of thrombosis 15, 16) . Adjunctive use of cilostazol with coronary stenting is thus becoming a more respect ed option 17). To date, several clinical trials compar ing ticlopidine and cilostazol as adjunctive anti platelet agents after coronary stenting have been reported, but most such trials have utilized only small subject populations.
In a previous study, we used meta-analysis to document the effectiveness of a 1-month adminis tration of cilostazol as compared to ticlopidine after elective coronary stenting 18). In the current study, we further compare cilostazol and ti clopidine by using a systematic review of the litera ture and meta-analysis techniques in order to evalu ate the long-term efficacy and safety with regard to the clinical outcome of cilostazol use after coro nary artery stent implantation.
Methods

Literature search
A comprehensive literature search was conduct ed using the Medline database (Pubmed (R)). All clinical studies that were published on Medline between January 1986 and March 2004 were examined. For Medline searches, a combination of the keywords "cilostazol" and "ticlopidine" was used with searches using the MeSH subject head ings "stents", "thrombosis" or "coronary res tenosis". We attempted to identify all clinical studies in both the English and Japanese languages. In addition to the search of the electronic database, manual searches were undertaken using reference lists from retrieved articles. In addition, several content experts and pharmaceutical companies were consulted for information about the existence of unpublished or recent studies.
Inclusion criteria
Two investigators (MH, KO) examined the title and abstract of each paper, and then the full paper if necessary. To be included in this meta-analysis, the study had to meet all the following criteria: prospective or retrospective, clinical study of adults after intracoronary artery stent implanta tion, including data from patients who successfully had their coronary artery stent implantation ter minated, had an efficacy evaluation using coronary artery angiography, and had a clinical follow-up period of more than 6 months that evaluated the clinical outcome.
Assessment of the quality of literature
We evaluated the quality of the literature using the score system developed by Morizane 19) , which is similar to a procedure that was adopted by Downs & Black 20), and Cho & Bero 21). Seven major items were evaluated for each study:study hypothesis, patient selection, patient characteristics, number of study patients, randomization and blinding, mea surements and definition of outcome, and statistical method. Quality was graded for each of the seven items on a scale of 0-15 (total maximum score= 100). Each item that was evaluated had a different maximal score due the nature of the item. In order to evaluate the quality of the studies, three investi gators (MH, KO, TS) independently evaluated the total scores for each of the respective studies. Differences were resolved by consensus. The qual ity of the studies was classified as follows, high (greater than 70 points), moderate (40 to 69 points), and low (less than 40 points).
Data extraction
We extracted the data for the clinical study design used, patient characteristics, implanted stent materials, the follow-up periods, antiplatelet drug and dose or dosage, and duration of drug adminis tration. For the outcome following stent placement, we assessed major adverse cardiac events (MACE) such as death and myocardial infarction (MI), rates of acute occlusion/thrombosis occur ring within 24 hours or subacute thrombosis/res tenosis occurring up to 1 month after the procedure, angiographic late restenosis (defined as diameter stenosis>50% at the 6-month follow-up) and addi tional target lesion revascularization (TLR) that was clinically needed. We also compared minimal lumen diameter of diseased vessels (MLD), late loss, loss index, or net gain with quantitative coro nary angiography (QCA) between the time point immediately after stent placement and the 6 subse quent months. To evaluate the adverse clinical events linked to the treatment, we assessed rates of bleeding, intracranial hemorrhage, vascular com plication, leukopenia, thrombocytopenia or neutropenia, skin rash, gastro-intestinal distur bance, hepatic impairment (elevated aminotrans ferase), and arrhythmia during the follow-up period.
Statistical analysis
For clinical outcomes such as for MACE and adverse clinical events, we used a ratio where data were expressed by an odds ratio (OR) and 95% confidence interval (CI). Statistical significance was judged using OR and 95% CI. Thus if the 95% CI did not include 1, the data indicated the presence of statistical significance. For the efficacy on QCA (MLD, late loss, loss index, and net gain), the parameters were treated as a continuous variable and analyzed by a general variance-based method where data are expressed as the weighted mean difference (WMD) and 95% CI, with statistical significance judged using the WMD and 95% CI. Thus, if the 95% CI did not include 0, the data indicated the presence of statistical significance. A test for homogeneity of pooled estimates of the data was performed using a Q statistic, which is referred to as a chi-square distribution with the degrees of freedom equal to the total number of studies minus 1. Statistical significance was expres sed at the level of p<0.05. The random effect model (DerSimonian-Laird method) was used for the pooled estimates where homogeneity was not observed for the data. In cases where homogeneity was observed, a fixed effect model (Peto method) was used for the pooled estimates. To avoid prob lems of bias and instability associated with estima tion of ORs, 0.5 was added to each cell of the four-fold and loss index ( 0.16 [-0.24, -0.08]) indicated a statistically sig nificant difference with regard to the benefit of the combined cilostazol with aspirin therapy versus the combined ticlopidine with aspirin therapy. The results of the meta-analysis for net gain (WMD [95% CI]:0.49 mm [0.30, 0.68]) also showed a statistically significant difference regarding the benefit of combined cilostazol with aspirin therapy versus combined ticlopidine with aspirin therapy, although only two papers contained statements about the net gain.
4, Adverse clinical events of cilostazol vs.
ticlopidine Figure 3 shows the OR for adverse clinical events between the two therapies. The results of the meta-analysis for all events except for elevated aminotransferase showed no statistically signifi cant differences between the therapies. Also, pooled estimates obtained by combining all events documented no statistically significant difference between the therapies (OR [95% CI]; 0.80 [0.47, 1.35]), which suggests that the combination of cilostazol plus aspirin does not differ from that of ticlopidine plus aspirin.
Discussion
We evaluated the long-term efficacy and safety with regard to clinical outcome for the oral anti platelet agents cilostazol or ticlopidine after intracoronary artery stent implantation by system atically reviewing the literature and using meta analysis techniques. The quality of all studies used had high to moderate scores (52 to 79 points) according to the score system for the validity of literature in clinical trials. The reason that the scores did not have extremely high point numbers may be related to the fact that 4 studies were open-label studies and 1 study was a retrospective observational study.
Meta-analysis of acute and late outcomes demon strated superiority in the prevention of restenosis and reduction of additional TLR in patients with cilostazol plus aspirin versus that seen for ti clopidine plus aspirin administrations, even though we observed no differences in the outcomes for the other categories of MACE. These results suggest that cilostazol may have an additive preventive effect against late restenosis, which is in part caused by intimal hyperplasia or smooth muscle cell proliferation. This protective effect may be due to cilostazol's thrombotic preventive effect. In the comparison between the two therapies with regard to the evaluation of QCA (Fig. 2) , cilostazol plus aspirin was also found to have a beneficial effect in MLD, late loss, loss index, and net gain versus that seen with ticlopidine plus aspirin.
The exact reason for these different effects between these two therapies is unclear, but other factors need to be considered. First, the follow-up and administration periods for the drugs in these studies were varied; 4-6 months in Tanabe 25)), ticlopidine was administered for only 1 month, a time period that was much shorter than for that seen with cilostazol. We also found a tendency in our analyses of MLD that the adminis tration of cilostazol for 6 months was superior to that of the 1 month, 4-6, or 6 months of ticlopidine administration. These results suggest that the com bination therapy of cilostazol plus aspirin may be effective in maintaining the diameter of vessels for a long time after stent implantation, but only when cilostazol is administered for 6 months, which coin cides with the peak incidence of late restenosis. Secondly, the results might be related to a differing pharmacological effects between cilostazol and ticlopidine. It is known that neointimal formation plays a major role in the restenotic process in stented coronary segments. Cilostazol has many mechanisms that may inhibit smooth muscle cell proliferation including acting on the phosphodiesterase III receptors 26,27), heparin-binding epidermal growth factor-like growth factor 28), or platelet derived growth factors 29). These mechanisms of cilostazol may play a part in the role of the inhibi tion of the restenosis process that occurs after coronary stenting.
In most studies, antiplatelet agents were started a few days before the coronary stenting. Ticlopidine and cilostazol was begun 2 days prior in Kamishir ado et al. 22) , and Park et al. 24 ), while in Tanabe et al. 26) , ticlopidine was started 4 days and cilostazol 2 days prior to the stenting. Cilostazol is known to achieve a maximum antiplatelet effect within 1 day 30), while ticlopidine needs at least 2 days to reach effective therapeutic concentrations in Fig. 1 The odds ratio for MACE for the outcome between the combined ticlopidine with aspirin therapy and the combined cilostazol with aspirin therapy TCL:ticlopidine, CLZ:cilostazol, OR:odds ratio, TLR:target lesion revascularization , n:number of patients who reported the outcome, N:total number of patients, a)Peto method Fig. 2 The difference between the combined cilostazol with aspirin therapy and the combined ticlopidine with aspirin therapy with regard to the change in minimal lumen diameter of diseased vessels (MLD), late loss, loss index, or net gain with quantitative coronary angiography at the end of the study TCL:ticlopidine, CLZ:cilostazol, WMD:weighted mean difference, n:number of lesions, a)general variance-based method, b)DerSimonian-Laird method Fig. 3 The odds ratio for the adverse clinical events between the combined ticlopidine with aspirin therapy and combined cilostazol with aspirin therapy TCL:ticlopidine, CLZ:cilostazol, OR:odds ratio, n:number of patients who reported the event, N:total number of patients, a) Veto method, b) DerSimonian-Laird method vivo 31,32) and has a very slow onset of the effect. In our meta-analysis, we were unable to clearly show that these differences are related to the phar macological characteristics seen in acute stent thrombosis and subacute stent thrombosis. We have previously examined the short-term efficacy (1 month) of cilostazol plus aspirin using a meta-analysis and did not find any statistical difference from that of ticlopidine plus aspirin after elective coronary stenting 18). On the other hand, our current study suggests that cilostazol's long-term efficacy is superior to that seen for ticlopidine. The reason for this may be due in part to the phar macological difference between the two drugs as mentioned above. For adverse clinical events (Fig. 3) , our results showed a lower incidence of bleeding, intracranial or cerebral hemorrhage in patients administered cilostazol plus aspirin (0%) or ticlopidine plus aspirin (0%, 0.4%). There were no differences in the incidences of other hematological problems such as leukopenia, thrombocytopenia, or neutropenia between two the therapies. However, ticlopidine plus aspirin (2.9%) therapy has a higher risk for elevated aminotransferase as opposed to cilostazol plus aspirin therapy (0.3%). It is well known that ticlopidine can cause hepatic impairment within the first 2-4 weeks after drug administration initiation. In all published studies that we examined, there were no cases of severe hepatic impairment even though the duration of ticlopidine administration was 1 month in 2 studies, 4 to 6 months in 1 study, and 6 months in 2 studies. It has also been reported that with cilostazol there is the possibility of an increased heart rate and a positive cardiac inotropic effect due to phos phodiesterase III inhibition 33). Our results found a tendency for a higher incidence of tachycardia or palpitations in patients administered cilostazol (2.5%), but these changes were not statistically significant. In patients with heart failure or with a high risk of arrhythmia, it is not clear as to what the influence of cilostazol may be and published studies do not always exclude such patients. Thus, heart rate or arrhythmia monitoring may be needed for high-risk patients. While our meta-analysis in dicated that there was a tendency for a lower inci dence of total adverse clinical events in patients with cilostazol (1.0%) versus that seen with ti clopidine (1.4%), there were no statistical signifi cant differences between the therapies. This result suggests that after coronary stenting, cilostazol therapy is almost the same as ticlopidine therapy with regard to safety.
It should be noted that this meta-analysis includes different drug administration and/or follow-up periods, and there is a possibility of publication bias, which could indicate that our results have some limitations. Stent designs also influence long-term angiographic outcome 34 '35) . The coil stents (Gianturo-Roubin I and II) have a higher restenosis rate compared with the slotted tube stent (Palmaz-Schatz) or the multicellular stents (MultiLink and NIR). Coil stents are as sociated with less initial gain because they allow acute recoil and tissue prolapse that is related to the greater amount of open space that is present between the stent struts. In our meta-analysis, the implanted stent designs differed among the studies. We did not take the stent designs into consideration in our study so we might need to carefully re evaluate our results from this point of view.
Recently, the adjunctive use of glycoprotein (GP) IIb/IIIa inhibitors has been found to be advantageous when administered in combination with intracoronary stent implantation because the GP IIb/IIIa receptors on platelets play a key role in the "final common pathway" of platelet-thrombus formation. Several studies have shown that when used as an adjunct to coronary intervention, intra venous GP IIb/IIIa inhibitors have a beneficial effect with regard to the reduction in restenosis, particularly in patients with unstable angina or in those with high-risk factors 36'37) . Furthermore it has become quite common for the thienopyridine deriv ative, clopidogrel, to be used in drug-eluting stents in the US and in Europe after coronary stenting. However, this drug has yet to be used in Japan. In studies that have compared clopidogrel and ti clopidine for efficacy/safety after coronary stent ing, it has been shown that the clinical efficacy is the same for both drugs and that the safety of clopidogrel is superior to that of ticlopidine [38] [39] [40] . Therefore, it will be interesting to see if a compari son of clopidogrel and cilostazol for long-term efficacy yields any differences with regard to use as an adjunctive antiplatelet therapy after coronary stenting.
In conclusion, we reviewed articles published from 1986 until the present and performed a meta analysis on 5 studies that examined the long-term efficacy and safety of cilostazol and ticlopidine coadministered with aspirin after coronary stent ing. The meta-analysis results suggest that a combi nation therapy of cilostazol and aspirin might be superior to that of ticlopidine and aspirin with regard to long-term efficacy, particularly as an adjunctive antiplatelet therapy for the prevention of late restenosis. 
